Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Korro Bio (Nasdaq: KRRO) granted non-statutory stock options to seven newly hired employees under its 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4). Four employees received options for a total of 6,000 shares at an exercise price of $10.59 per share, effective June 10, 2026, and three employees received options for a total of 17,000 shares at $14.72 per share, effective July 8, 2026.

The options have ten-year terms and vest over four years, with 25% vesting on the first employment anniversary and the remaining 75% vesting in 36 equal monthly installments, subject to continued service. According to Korro Bio, the independent Compensation Committee approved these inducement awards as a material condition of employment.

Market reaction after inducement option grants: KRRO -7.28% in the Jul 13 session

-7.28%

6 alerts

-7.28% Session close to close

-2.4% Trough in 1 hr 28 min

$212.30M Market Cap

0.2x Rel. Volume

In the Jul 13 session, KRRO declined 7.28%, reflecting a notable negative market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.3% in the session following this news. A sharp decline following these Nasdaq Rul...

Analysis

The stock moved -7.3% in the session following this news. A sharp decline following these Nasdaq Rule 5635(c)(4) inducement grants would fit a backdrop of recent insider net selling and active resale registrations, even though the option awards themselves are standard hiring tools rather than a primary capital raise.

Key Figures

Option grant shares: 6,000 shares Exercise price: $10.59 per share Option grant shares: 17,000 shares +5 more

8 metrics

Option grant shares 6,000 shares Nonstatutory options to four new employees

Exercise price $10.59 per share Grant effective date June 10, 2026

Option grant shares 17,000 shares Nonstatutory options to three new employees

Exercise price $14.72 per share Grant effective date July 8, 2026

Option term 10 years Term of inducement stock options

Vesting period 4 years Options vesting schedule based on continued service

Initial vesting tranche 25% Cliff vesting on first anniversary of start date

Subsequent installments 36 monthly installments Remaining 75% of options vest monthly

Historical Context

5 past events · Latest: May 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 27	Conference presentation	Neutral	+11.6%	Jefferies healthcare conference presentation highlighting OPERA RNA-editing platform.
May 19	Pipeline update	Positive	-2.7%	Selection of KRRO-111 AATD candidate with strong preclinical editing data.
May 15	Inducement grant	Neutral	-2.1%	Single-employee stock option inducement grant under 2026 Inducement Plan.
May 07	Earnings report	Positive	-3.4%	Q1 2026 update with $157.1M cash and extended runway into H2 2028.
May 05	Investor conferences	Neutral	+6.0%	Participation in HCW BioConnect and RBC healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Korro headlines have often seen price moves that diverge from the apparent fundamental tone of the news.

Key Terms

nonstatutory stock options, nasdaq listing rule 5635(c)(4)

2 terms

nonstatutory stock options financial

"Korro granted four new employees nonstatutory stock options to purchase 6,000 shares"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to seven newly hired employees.

Korro granted four new employees nonstatutory stock options to purchase 6,000 shares, in the aggregate, of Korro’s common stock at an exercise price of $10.59 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, June 10, 2026; and granted three new employees nonstatutory stock options to purchase 17,000 shares, in the aggregate, of Korro’s common stock at an exercise price of $14.72 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, July 8, 2026. The options each have a ten-year term and vest over four years, with 25% of the shares vesting on the first anniversary of each such employee’s applicable start date and the remaining 75% vesting in 36 equal monthly installments on each monthly anniversary thereafter until the fourth anniversary of such employee’s applicable start date, subject to the employee’s continued service with Korro through each applicable vesting date.

These grants were approved by Korro’s independent Compensation Committee pursuant to Korro’s 2026 Inducement Plan and were made as an inducement material to the employee’s acceptance of employment with Korro in accordance with Nasdaq Listing Rule 5635(c)(4).

About Korro

Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of oligonucleotides that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology.  As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro Bio Contact Information

Investor & Media Contact
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269

FAQ

What inducement stock option grants did Korro Bio (KRRO) announce on July 10, 2026?

Korro Bio announced non-statutory stock option grants to seven new employees totaling 23,000 shares. According to Korro Bio, four employees received options for 6,000 shares and three employees received options for 17,000 shares of common stock under the 2026 Inducement Plan.

What are the exercise prices of the new Korro Bio (KRRO) inducement stock options?

The inducement options have exercise prices of $10.59 and $14.72 per share. According to Korro Bio, 6,000 shares were granted at $10.59 effective June 10, 2026, and 17,000 shares at $14.72 effective July 8, 2026, matching Nasdaq closing prices on those dates.

How do the Korro Bio (KRRO) inducement stock options vest for new employees?

The inducement options vest over four years with a standard time-based schedule. According to Korro Bio, 25% of each grant vests on the first employment anniversary, and the remaining 75% vests in 36 equal monthly installments, contingent on continued service through each vesting date.

Why were the July 2026 Korro Bio (KRRO) option grants made under Nasdaq Listing Rule 5635(c)(4)?

The grants were made as employment inducement awards permitted under Nasdaq Listing Rule 5635(c)(4). According to Korro Bio, its independent Compensation Committee approved these non-statutory options as a material inducement to the seven employees’ acceptance of employment with the company.

What is the term length of the new Korro Bio (KRRO) inducement stock options?

Each inducement option grant has a ten-year term from its effective grant date. According to Korro Bio, the options granted on June 10, 2026, and July 8, 2026, remain exercisable for ten years, subject to the company’s equity plan provisions and continued employment conditions.

Under which equity plan did Korro Bio (KRRO) issue the July 2026 inducement stock options?

The options were issued under Korro Bio’s 2026 Inducement Plan dedicated to new-hire awards. According to Korro Bio, this plan allows the Compensation Committee to grant non-statutory stock options as material inducements to attract and retain newly hired employees, consistent with Nasdaq rules.